Published in Diabetologia on January 01, 2002
Excessive adipose tissue infiltration in skeletal muscle in individuals with obesity, diabetes mellitus, and peripheral neuropathy: association with performance and function. Phys Ther (2008) 1.78
Inflammation in the pathogenesis of microvascular complications in diabetes. Front Endocrinol (Lausanne) (2012) 1.24
Obesity and inflammation: epidemiology, risk factors, and markers of inflammation. Int J Endocrinol (2013) 1.12
High glucose concentrations induce TNF-α production through the down-regulation of CD33 in primary human monocytes. BMC Immunol (2012) 1.03
Post-load hyperglycemia as an important predictor of long-term adverse cardiac events after acute myocardial infarction: a scientific study. Cardiovasc Diabetol (2010) 0.94
Role of C reactive protein (CRP) in leptin resistance. Curr Pharm Des (2014) 0.93
Frequency of TLR 2, 4, and 9 gene polymorphisms in Chinese population and their susceptibility to type 2 diabetes and coronary artery disease. J Biomed Biotechnol (2012) 0.91
Rarity of TLR4 Asp299Gly and Thr399Ile polymorphisms in the Korean population. Yonsei Med J (2008) 0.86
The common inflammatory etiology of depression and cognitive impairment: a therapeutic target. J Neuroinflammation (2014) 0.85
Arsenite activates NFκB through induction of C-reactive protein. Toxicol Appl Pharmacol (2012) 0.80
Relation between C-reactive protein and impaired fasting glucose in obese subjects. Inflammation (2012) 0.79
Insulin resistance and left ventricular mass in non-diabetic hemodialysis patients. Curr Ther Res Clin Exp (2012) 0.78
Cerebral ischemic damage in diabetes: an inflammatory perspective. J Neuroinflammation (2017) 0.78
Relationship between Type 2 Diabetes and Inflammation Diseases: Cohort Study in Chinese Adults. Iran J Public Health (2015) 0.75
Plasma Metanephrines Are Associated With Glucose Metabolism in Patients With Essential Hypertension. Medicine (Baltimore) (2015) 0.75
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia (2010) 4.33
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia (2006) 2.82
Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care (2000) 2.59
Subclinical inflammation is strongly related to insulin resistance but not to impaired insulin secretion in a high risk population for diabetes. Metabolism (2002) 1.68
Increased serum procalcitonin in newborn infants without infection. Clin Chem (1998) 1.67
Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia (1995) 1.63
Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data. Diabetologia (2004) 1.57
Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals. Diabetologia (1998) 1.47
The postprandial state and the risk of atherosclerosis. Diabet Med (1997) 1.47
Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care (1999) 1.46
Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis (1999) 1.40
[Prevalence of newly diagnosed type 2 diabetes, impaired glucose tolerance and abnormal fasting glucose in a high risk population. Data from the RIAD study using new diagnostic criteria for diabetes]. Dtsch Med Wochenschr (1999) 1.40
Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab (2004) 1.39
Interaction of mitochondrial targeting signals with acidic receptor domains along the protein import pathway: evidence for the 'acid chain' hypothesis. EMBO J (1998) 1.30
Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia (2005) 1.29
Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology (1997) 1.24
Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev (2005) 1.18
A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial. Diabet Med (2005) 1.17
Increased intimal-medial thickness in newly detected type 2 diabetes: risk factors. Diabetes Care (1999) 1.16
Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol (2002) 1.16
Mass spectrometric identification of proteins released from mitochondria undergoing permeability transition. Cell Death Differ (2000) 1.15
The Diabetes Intervention Study (DIS): a cooperative multi-intervention trial with newly manifested type II diabetics: preliminary results. Monogr Atheroscler (1985) 1.15
Comparison of the prevalence of the metabolic syndrome by WHO, AHA/NHLBI, and IDF definitions in a German population with type 2 diabetes: the Diabetes in Germany (DIG) Study. Horm Metab Res (2007) 1.12
Immune adherence in renal glomeruli. Complement receptor sites on glomerular capillary epithelial cells. Am J Pathol (1977) 1.11
Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia (2005) 1.09
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1). Diabet Med (2013) 1.08
Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med (2007) 1.08
Metabolic diseases and their possible link to risk indicators of periodontitis. J Periodontol (2000) 1.03
["Diabetes in Germany"(DIG) study. A prospective 4-year-follow-up study on the quality of treatment for type 2 diabetes in daily practice]. Dtsch Med Wochenschr (2009) 0.97
Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. Diabet Med (2010) 0.96
Impaired fasting glucose is not a risk factor for atherosclerosis. Diabet Med (1999) 0.95
Very fast ultracentrifugation of serum lipoproteins: influence on lipoprotein separation and composition. Biochim Biophys Acta (1995) 0.94
An update on preventive and regenerative therapies in diabetes mellitus. Pharmacol Ther (2008) 0.94
Relationship between morphological changes and lipid-lowering action of p-chlorphenoxyisobutyric acid (CPIB) on hepatic mitochondria and peroxisomes in man. Atherosclerosis (1983) 0.93
In vivo evidence for increased apolipoprotein A-I catabolism in subjects with impaired glucose tolerance. Diabetes (1998) 0.91
Work absenteeism in type 2 diabetes mellitus: results of the prospective Diabetes Intervention Study. Diabete Metab (1993) 0.91
Control of post-prandial hyperglycemia--an essential part of good diabetes treatment and prevention of cardiovascular complications. Nutr Metab Cardiovasc Dis (2002) 0.91
The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes. Exp Clin Endocrinol Diabetes (2004) 0.90
Procalcitonin as a marker for the early diagnosis of severe infection after thermal injury. J Burn Care Rehabil (1999) 0.89
Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes. Acta Diabetol (2013) 0.89
Effects of p-chlorophenoxyisobutyric acid (CPIB) on the human liver. Atherosclerosis (1980) 0.88
The adipocyte volume in human adipose tissue: II. Observations in diabetes mellitus, primary hyperlipoproteinemia and weight reduction. Int J Obes (1978) 0.87
Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. Diabetes Obes Metab (2003) 0.86
Search for mitochondrial DNA mutation at position 3243 in German patients with a positive family history of maternal diabetes mellitus. Exp Clin Endocrinol Diabetes (2001) 0.86
Coagulation markers predict survival in cancer patients. Thromb Haemost (2002) 0.86
Alcohol consumption and other psycho-social conditions as important factors in the development of diabetic foot ulcers. Diabet Med (2011) 0.86
Effect of increased protein intake and nutritional status on whole-body protein metabolism of AIDS patients with weight loss. Metabolism (1995) 0.84
Improved metabolic control by Ipomoea batatas (Caiapo) is associated with increased adiponectin and decreased fibrinogen levels in type 2 diabetic subjects. Diabetes Obes Metab (2007) 0.84
Childhood education: a review of effects on the woman and her family. Fam Community Health (1986) 0.84
Prevalence and atherosclerosis risk in different types of non-diabetic hyperglycemia. Is mild hyperglycemia an underestimated evil? Exp Clin Endocrinol Diabetes (2000) 0.84
Association between reduced human leukocyte antigen (HLA)-DR expression on blood monocytes and increased plasma level of interleukin-10 in patients with severe burns. Clin Chem Lab Med (1999) 0.83
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Horm Metab Res (2008) 0.83
European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol (1998) 0.83
Plasma prostacyclin and thromboxane concentrations in 160 normotensive, hypotensive, and preeclamptic patients during pregnancy, delivery, and the post partum period. J Perinat Med (1993) 0.83
[Intima-media thickness in healthy probands without risk factors for arteriosclerosis]. Dtsch Med Wochenschr (2001) 0.83
Use of insulin in type 2 diabetes: what we learned from recent clinical trials on the benefits of early insulin initiation. Diabetes Metab (2014) 0.82
Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk -- results from the PIOSTAT study. Horm Metab Res (2007) 0.82
Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens (2010) 0.82
2-Chloro-4-nitrophenyl-beta-D-maltoheptaoside: a new substrate for the determination of alpha-amylase in serum and urine. J Clin Chem Clin Biochem (1984) 0.81
Relationship between HbA1c on target, risk of silent hypoglycemia and glycemic variability in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes (2011) 0.81
The histologic characteristics of primary and restenotic carotid plaque. J Surg Res (1998) 0.81
Structures and relative stability of medium-sized silicon clusters. V. Low-lying endohedral fullerenelike clusters Si31-Si40 and Si45. J Chem Phys (2006) 0.80
The metabolic syndrome--a postprandial disease? Horm Metab Res (2006) 0.80
Clinical efficacy and safety of cerivastatin: summary of pivotal phase IIb/III studies. Am J Cardiol (1998) 0.80
[Effect of peripheral venous parenteral feeding on the postoperative protein status]. Infusionsther Klin Ernahr (1979) 0.80
Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals. Eur J Clin Pharmacol (1997) 0.80
Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study. Horm Metab Res (2009) 0.80
Significance of antibodies to cardiolipin in unselected patients with systemic lupus erythematosus: clinical and laboratory associations. The SLE Study Group. Rheumatol Int (1995) 0.80
Effects of salinomycin on human bone marrow-derived mesenchymal stem cells in vitro. Toxicol Lett (2013) 0.80
Beneficial effects on serum lipids in noninsulin dependent diabetics by acarbose treatment. Arzneimittelforschung (1991) 0.80
[Challenge in diabetes therapy: effects of glitazones beyond blood glucose control]. Dtsch Med Wochenschr (2009) 0.79
Measurement of CEA, TPA, neopterin, CA125, CA153 and CA199 in sera of pregnant women, umbilical cord blood and amniotic fluid. Gynecol Obstet Invest (1989) 0.79
Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with Type 2 diabetes. Diabetes Res Clin Pract (2002) 0.79
Relation of free and specifically bound leptin to insulin secretion in patients with impaired glucose tolerance (IGT). Exp Clin Endocrinol Diabetes (1999) 0.79